

N	Survey/Research Title	Research/survey period	Research carried out by:	Sponsor:	Main Contact Person ( Study PI/Co-PI )	E-mail
1	CRDF, GEX1-002711-TB-06 Determination of Susceptibility to Some Second-Line Drugs of <i>Mycobacterium tuberculosis</i> Strains Isolated in the Republic of Georgia	2006-2008	National Center for Tuberculosis and Lung Diseases	Civilian Research and Development Foundation, USA	Lamara Vashakidze	<a href="mailto:lamara-vashakidze@yandex.ru">lamara-vashakidze@yandex.ru</a>
2	CRDF, GEX1-002712-TB-06 Characterization of <i>Mycobacterium tuberculosis</i> Gene Expression Patterns During Growth in the Human Lung	2006-2008	National Center for Tuberculosis and Lung Diseases	Civilian Research and Development Foundation, USA	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
4	CRDF, GEB1-002725-TB-07 <i>Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug induced hepatotoxicity among new pulmonary tuberculosis patients in the country of Georgia</i>	2007-2010	National Center for Tuberculosis and Lung Diseases	Civilian Research and Development Foundation, USA	Nino Lomtadze Lali Kupreishvili	<a href="mailto:nlomtadze@gmail.com">nlomtadze@gmail.com</a>
6	Latent tuberculosis Infection (LTBI) among Health-care Workers (HCW) in the Country of Georgia	2008-2012	National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Veriko Mirtskhulava	<a href="mailto:verikomir@yahoo.com">verikomir@yahoo.com</a>
7	Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Georgia: A Population Based Study	2005-2006	National Center for tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Nino Lomtadze	<a href="mailto:nlomtadze@gmail.com">nlomtadze@gmail.com</a>
8	The Use of a Molecular Diagnostic Test HAIN MTBDRplus among AFB Smear Positive Tuberculosis Suspects	2009-2011	National Center for tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
9	Impact of Vitamin D Supplementation on Host Immunity to <i>Mycobacterium tuberculosis</i> and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia	2009-2012	National Center for tuberculosis and Lung Diseases	Emory University Global Health Institute National Institutes of Health grants UL1 TR000454 (Atlanta Clinical and Translational Science Institute), K24 DK096574, D43 TW007124, D43 TW001042, K23 AR054334, K23 AI103044, T32 DK007298- 3251	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
10	CRDF GEB2 – 2935 – TB - 08 Risk Factors for Extensively Drug Resistant Tuberculosis and Evaluation of the GenoType MTBDRplus and MTBDRsl assays for rapid M/XDR TB testing in Country of Georgia	2009-2012	National Center for tuberculosis and Lung Diseases Emory University School of Medicine, Atlanta, GA, USA	Civilian Research and Development Foundation, USA	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
11	Poor treatment outcomes among MDR TB patients in Georgia	2009-2010	The National Center for Tuberculosis and Lung Diseases, Emory University	NIH/Fogarty International Center grant D43TW007124	Medea Gegia	<a href="mailto:mgegia@gmail.com">mgegia@gmail.com</a>
12	Outcomes among Tuberculosis Patients with Isoniazid Resistance in Georgia, 2007-2009	2010-2011	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Medea Gegia	<a href="mailto:mgegia@gmail.com">mgegia@gmail.com</a>

13	Contact Investigation for Tuberculosis in Georgia, Tbilisi (Pilot Project)	2011-2014	The National Center for Tuberculosis and Lung Diseases	International Society for Infectious Disease (ISID); Emory University	Tsira Chakhaia	<a href="mailto:tschakhaia@gmail.com">tschakhaia@gmail.com</a>
16	Smoking Prevalence among pulmonary tuberculosis patients in the Republic of Georgia	2011-2012	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Medea Gegia	<a href="mailto:mgegia@gmail.com">mgegia@gmail.com</a>
17	Retrospective Analysis of the Contacts of TB Patients	2012	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Tsira Chakhaia	<a href="mailto:tschakhaia@gmail.com">tschakhaia@gmail.com</a>
18	Poor treatment outcomes among XDR TB patients in Georgia	2012	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Medea Gegia	<a href="mailto:mgegia@gmail.com">mgegia@gmail.com</a>
19	Contact Investigation and genotyping of M. tuberculosis strains for Tuberculosis in Georgia, Tbilisi.	2014 -	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Tsira Chakhaia	<a href="mailto:tschakhaia@gmail.com">tschakhaia@gmail.com</a>
21	Halt Study	2012-2013	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Maia Kipiani	<a href="mailto:maiaagechkori@yahoo.com">maiaagechkori@yahoo.com</a>
22	GIPP #p496, Bacteriophages against biofilms	2012-2013	The National Center for Tuberculosis and Lung Diseases	Global Initiatives for Proliferation Prevention (GIPP). This is a nonproliferation program of the National Nuclear Security Administration (NNSA) at the U.S. Department of Energy.	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
23	Performance of the GeneXpert for TB case finding among HIV-infected patients in Tbilisi, Georgia	2012-2013	The National Center for Tuberculosis and Lung Diseases	National Institutes of Health (NIH), under NIH/National Institute of Allergy and Infectious (Award No. 5 P30AI050409-15, CFDA No. 93.855)	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
24	Selection of appropriate treatment and infection control measures by integrated high throughput genotyping and drug resistance determination of M. tuberculosis clinical isolates	2012-2014	The National Center for Tuberculosis and Lung Diseases	Royal Tropical Institute, Biomedical Research, Amsterdam, Netherlands	Rusudan Aspindzelashvili	<a href="mailto:asporusiko@yahoo.com">asporusiko@yahoo.com</a>
25	Adjuvant Surgical Resection for M/XDR	2011-2012	The National Center for Tuberculosis and Lung Diseases	NIH/Fogarty International Center grant D43TW007124	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
27	Immunologic Markers	2013	The National Center for Tuberculosis and Lung Diseases	NHDetect Singapore Group	Nestani Tukvadze Leila Goginashvili	<a href="mailto:l.goginashvili@tbgeo.ge">l.goginashvili@tbgeo.ge</a>
28	Evaluation of Xpert MTB/Rif performance among pulmonary and extrapulmonary TB suspects	2012- 2013	The National Center for Tuberculosis and Lung Diseases	Global Fund	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
29	Evaluation of MTBDRsl test among smear positive and smear negative pulmonary and extrapulmonary TB suspects	2013	The National Center for Tuberculosis and Lung Diseases	Global Fund	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
30	Efficacy of adjunctive therapy with Salkhino in patients with Pulmonary Tuberculosis Clinical Trial	2012-2015	The National Center for Tuberculosis and Lung Diseases	LTD "SALKHINO"	Lamara Vashakidze	<a href="mailto:lamara-vashakidze@yandex.ru">lamara-vashakidze@yandex.ru</a>
31	Efficacy and Safety of Intercostal Nerve Block with Investigational Production Subjects Undergoing Posterolateral Thoracotomy Clinical Trial	2012-2016	The National Center for Tuberculosis and Lung Diseases	PaciraPharmaceuticals, Inc. SMO PHARMINA, LTD	Shota Gogishvili Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>

32	Efficacy and safety of Fluticasone Fuorate/Vilanterol Inhalation Powder 100/25mcg with placebo in Subjects with moderate COPD and a history of increased cardiovascular diseases Clinical Trial	2011-2017	The National Center for Tuberculosis and Lung Diseases	GlaxoSmithKline Research and Development Ltd CRO: Parexel	Kakha Vacharadze Davit Chkonia	<a href="mailto:Kakhavacharadze@yahoo.com">Kakhavacharadze@yahoo.com</a>
33	efficacy and Safety of 2.5 mkg and 5 mkg Trotronium Inhalation Solution Clinical Trial	2010-2013	The National Center for Tuberculosis and Lung Diseases	Bochringer Ingelheim Pharma Ges mbH CRO: Worldwide Clinical trials Russia LLC	Kakha Vacharadze	<a href="mailto:Kakhavacharadze@yahoo.com">Kakhavacharadze@yahoo.com</a>
34	Compensatory Evolution and Epistasis in Multidrug-resistant Mycobacterium tuberculosis	2013-2017	The National Center for Tuberculosis and Lung Diseases	European Research Council (ERC) "Starting Grant" awarded to Prof. Gagneux	Rusudan Aspindzelashvili	<a href="mailto:asporusiko@yahoo.com">asporusiko@yahoo.com</a>
35	Genomic characterization of multi drug resistant Tuberculosis in Georgia (Award Agreement # 60368)	2014	The National Center for Tuberculosis and Lung Diseases	Georgian Research and Development Foundation Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Nino Bablishvili	<a href="mailto:nino_bablishvili@yahoo.com">nino_bablishvili@yahoo.com</a>
36	"Validation of new MDR-TB diagnostic tools in diverse setting"	2013-2015	The National Center for Tuberculosis and Lung Diseases	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
37	"Impact of Adjunctive Surgical Therapy in the Treatment of MDR and XDR-TB"	2014-2015	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
38	A Phase III Open- Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 5 months in Adult Subjects with Drug-Sensitive Smear- or GeneXpert Positive Pulmonary Tuberculosis and after 5 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear Positive Pulmonary Tuberculosis (NC-006 (M-Pa-Z))	2015 -2018	The National Center for Tuberculosis and Lung Diseases	TB Alliance	Leila Goginashvili	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
41	Pharm-TB Intracavitary Drug Levels and Drug Resistance in Tuberculosis	2013-2014	The National Center for Tuberculosis and Lung Diseases	Emory University	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
42	CIFAR	2014-2018	The National Center for Tuberculosis and Lung Diseases	Emory University	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
43	SAMPLE COLLECTION	2014-2018	The National Center for Tuberculosis and Lung Diseases	FIND	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
45	Xpert Ultra trial: External Alpha Study	2015	The National Center for Tuberculosis and Lung Diseases	FIND	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
46	MTBDRsl Evaluation Study	2015	The National Center for Tuberculosis and Lung Diseases	FIND	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
47	Xpert Ultra trial: Beta study Phase 0	2015	The National Center for Tuberculosis and Lung Diseases	FIND	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
48	Ultra Beta_1-2nd phase	2016-2017	The National Center for Tuberculosis and Lung Diseases	FIND	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
50	Evaluation of efficacy of Plasma Cluster technology for ensuring proper IC in TB Hospital	2015	The National Center for Tuberculosis and Lung Diseases	HUMAN DIAGNOSTIC GEORGIA Ltd	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>

51	European network of HIV/AIDS cohort studies to coordinate at European and International level clinical research on HIV/AIDS	2013-2015	The National Center for Tuberculosis and Lung Diseases	University of Copenhagen, Copenhagen HIV Programm (TB-HIV '15)	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>
52	The epidemiology of adverse reaction associated with second line anti-tuberculosis drugs among M/XDR TB patients in Tbilisi, Georgia	2015	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Mariana Buziashvili	<a href="mailto:mari.buziashvili@yahoo.com">mari.buziashvili@yahoo.com</a>
53	Effects of tobacco use on tuberculosis treatment : Knowledge & attitudes of health care workers	2015	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Lasha Darchia	<a href="mailto:Lasha_darchia@yahoo.com">Lasha_darchia@yahoo.com</a>
54	Prevalence of Depression and Associated Risk Factors among Multidrug-Resistant Tuberculosis Patients in the Country of Georgia	2015	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Maia Alkhazishvili	
55	Clinical Impact of the Xpert MTB/RIF Assay among Sputum Smear Negative Tuberculosis Patients in the Country of Georgia	2015	The National Center for Tuberculosis and Lung Diseases	Emory-Georgia TB Research Training Program (EGTB-RTP) NIH/Fogarty International Center grant D43TW007124	Maia Kipiani	<a href="mailto:maiagechkori@yahoo.com">maiagechkori@yahoo.com</a>
56	Compassionate use of delamanid (OPC-67683) for patients with pulmonary multidrug-resistant tuberculosis with limited therapeutic options	2015	The National Center for Tuberculosis and Lung Diseases	Medecins Sans Frontieres	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>
57	Expanding global knowledge of tuberculosis by establishing the Georgia Tuberculosis Portal.	2015	The National Center for Tuberculosis and Lung Diseases	NIAID	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
58	Pharmacokinetics of second-line anti-tuberculosis drugs among patients with multidrug-resistant tuberculosis	2015	The National Center for Tuberculosis and Lung Diseases	International Science and Technology Center (ISTC)	M.Kipiani, R.Kempker (PI)	<a href="mailto:maiagechkori@yahoo.com">maiagechkori@yahoo.com</a>
59	Efficacy and safety of new inhaled antibiotic Pulmaquin Clinical Trial	2015	The National Center for Tuberculosis and Lung Diseases	The National Center for Tuberculosis and Lung SMO Pharmina	Shota Gogishvili	
62	5% Initiative Chanell 1, project 1 Contact investigations	2016	The National Center for Tuberculosis and Lung Diseases	Expertise France	Nestani Tukvadze	
63	5% Initiative Chanell 2, project 2	2017	The National Center for Tuberculosis and Lung Diseases	Expertise France	Nino Lomtadze	
65	Study of TB lesions obtained in surgery: in search of best biomarkers correlating with TB pathology, clinical features, MDR cases and prognostic (SH-TBL).	2016	The National Center for Tuberculosis and Lung Diseases	Emory University	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
66	STREAM Phase II	2016	The National Center for Tuberculosis and Lung Diseases	The Union	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>
67	"Pilot Study to estimate the potential efficacy and safety of using Adjunctive Ibuprofen for the Treatment of XDR Tuberculosis" (NSAIDS-XDR-TB)	2016	The National Center for Tuberculosis and Lung Diseases	Institute Germans Trias I Pujol	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>

69	A Phase 3 partially-blinded, randomized trial assessing the safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary infection of either extensively drug-resistant tuberculosis (XDR-TB), pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB)(Ze NIX-TB Trial)	2017-2021	The National Center for Tuberculosis and Lung Diseases	Tb Alliance	Lali Mikiashvili	<a href="mailto:lali.mikiashvili@tbgeo.ge">lali.mikiashvili@tbgeo.ge</a>
70	Compensatory Evolution and Epistasis in Multidrug-resistant Mycobacterium tuberculosis” (EVODRTB), to the National Center for Tuberculosis and Lung Diseases (Evaluation of Xpert/Ultra system)	2017	The National Center for Tuberculosis and Lung Diseases	Find	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
71	End-TB Clinical Trial	2017	The National Center for Tuberculosis and Lung Diseases	Medecins Sans Frontieres	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>
72	“Retrospective Study of TB lesions obtained in surgery: in search of best biomarkers correlating with TB pathology, clinical features, MDR cases and prognostic (SH-TBL)	2016-2019	The National Center for Tuberculosis and Lung Diseases	Institute Germans Trias I Pujol	Sergo Vashakidze	<a href="mailto:sergovashakidze@yahoo.com">sergovashakidze@yahoo.com</a>
73	Double-Blind, randomized, masked, placebo-controlled, Clinical Trial to Investigate the efficacy of the nutraceutical Nyadtum rasae administered to contact of active tuberculosis in the Republic of Georgia	2016-	The National Center for Tuberculosis and Lung Diseases	Institute Germans Trias I Pujol	Nestan Tukvadze	marikushane@yahoo.com
74	A Clinical Pharmacology Study of a Novel Drug Regimen for pre XDR and XDR Tuberculosis	2016-2018	The National Center for Tuberculosis and Lung Diseases	NIH/R21	Maia Kipiani	<a href="mailto:maiagegechkori@yahoo.com">maiagegechkori@yahoo.com</a>
75	Community engagment project	2017-	The National Center for Tuberculosis and Lung Diseases	TB Alliance	Tsira Chakhaia	<a href="mailto:tschakhaia@gmail.com">tschakhaia@gmail.com</a>
76	Implementation of New Drug-Resistant Tuberculosis Treatments (Output 1)	2017-	The National Center for Tuberculosis and Lung Diseases	Medecins Sans Frontieres	Nana Kiria	<a href="mailto:nana_kiria@yahoo.com">nana_kiria@yahoo.com</a>
77	An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid (TB Meningities)	2018-	The National Center for Tuberculosis and Lung Diseases	Emory university	Maia Kipiani, Russell Kempker	<a href="mailto:maiagegechkori@yahoo.com">maiagegechkori@yahoo.com</a>
78	An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPamZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPamZ in Adult Participants with Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) (SIMPLICI-TB)	2018-	The National Center for Tuberculosis and Lung Diseases	TB Alliance	Marika Eristavi	<a href="mailto:marikaeristavi@gmail.com">marikaeristavi@gmail.com</a>
79	Developmenr of network for imporving diagnosis and treatment of patients with cavitating tubreculosis	2018-2019	The National Center for Tuberculosis and Lung Diseases	University of Leicester, Leicester, United Kingdom	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>

80	“Evaluation of the response to HBHA in combination with IGRA as a supportive tool for monitoring anti tuberculosis-therapy efficacy and diagnosis of tuberculosis stages”	2018-2020	The National Center for Tuberculosis and Lung Diseases	HINTT-Study for HBHA-IGRA tool for tuberculosis diagnosis	Nestan Tukvadze, Eka Kokhreidze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
81	Sample prep & NAAT (150 patients, 6 months)	2019	The National Center for Tuberculosis and Lung Diseases	FIND	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
82	Performance of the molecular test Xpert MTB/RIF Ultra for early detection of tuberculosis at Primary Health Carefacilities in Georgia: a parallel cluster randomizedcontrolledtrial	2019	The National Center for Tuberculosis and Lung Diseases	FIND	Nestani Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
83	An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid	2019-2020	The National Center for Tuberculosis and Lung Diseases	NIH	Maia Kipiani	<a href="mailto:maiagegechkori@yahoo.com">maiagegechkori@yahoo.com</a>
84	Phase 2b Randomized trial to estimate the potential efficacy and safety of a repurposed drug, aspirin, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen (AAS-TB)	2020-2024	The National Center for Tuberculosis and Lung Diseases	HORIZONE 2020	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
85	HDT-TB	2020-2024	The National Center for Tuberculosis and Lung Diseases	HORIZONE 2020	Nestan Tukvadze	<a href="mailto:marikushane@yahoo.com">marikushane@yahoo.com</a>
86						
87						









Completed
Completed
Completed
Completed
Completed
Ongoing
Completed
Completed
Completed
Completed
Completed
Completed
Ongoing
Completed

Ongoing
Ongoing
Completed
Ongoing
Completed
Ongoing
Ongoing
Ongoing
Ongoing
Ongoing

